non-small cell lung cancer


Also found in: Medical, Wikipedia.
Related to non-small cell lung cancer: adenocarcinoma

non-small cell lung cancer

 (nŏn′smôll′)
n.
Any of several lung cancers, especially an adenocarcinoma, squamous cell carcinoma, or large cell carcinoma, that derive from cells of the epithelium and differ in structure from small cell lung cancer.
References in periodicals archive ?
Lung cancer can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer according to the tissue type, with SCLC accounting for approximately 10 to 15% of all lung cancer cases.
M2 PRESSWIRE-August 22, 2019-: Non-Small Cell Lung Cancer Market Huge Growth Opportunities and Challenges to Watch in 2019
Neptune was a randomised, open-label trial of previously untreated patients with stage four non-small cell lung cancer. The primary analysis population was patients with a high number of mutations in their tumour DNA.
The drug was also approved to treat adults with metastatic non-small cell lung cancer and ROS1-positive tumors.
AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations.
M2 EQUITYBITES-July 8, 2019-Genprex Updates on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer
M2 PHARMA-June 4, 2019-AstraZeneca Touts Imfinzi is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer
Merck announced the presentation of five-year efficacy and safety data for Keytruda, the company's anti-PD-1 therapy, as monotherapy in patients with advanced non-small cell lung cancer from the first Keynote trial.
Medicine company Eli Lilly and Company (NYSE:LLY) reported on Thursday the US Food and Drug Administration's (FDA) approval for the new indication for ALIMTA (pemetrexed for injection) in combination with KEYTRUDA (pembrolizumab) for the treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC).
Sharon Pine received a $200,000 Lung Cancer Discovery Award from the American Lung Association to examine potential new treatment options for patients with a sub-type of non-small cell lung cancer.
Lung cancer can be broadly classified into two major types - non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).